Mettler-Toledo earnings date
Mettler-Toledo (MTD) Q3 2026 Earnings Report
MX:MTD Q3 2026 EPS Results
- Actual EPS
- MXN 233.84
- Consensus EPS
- MXN 225.62
- Beat/Miss
- Beat by +MXN 8.22
- One Year Ago EPS
- MXN 207.42
MX:MTD Q3 2026 Revenue Results
- Actual Revenue
- MXN 20.36B
- Expected Revenue
- MXN 19.93B
- Beat/Miss
- Beat by +MXN 425.69M
- YoY Revenue Growth
- +6.27%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Mettler-Toledo's next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. The company reported broad-based 6% organic sales growth, 13% adjusted EPS growth, improved margins, strong momentum in China and emerging markets, a raised 2026 outlook, and 10% to 12% expected adjusted EPS growth for 2027. Management also highlighted improving laboratory demand, automation and digitalization opportunities, strategic investments, and growing onshoring activity. The main cautions were subdued European conditions, food retail and near-term product-inspection softness, higher material and transportation costs, tariff and foreign-exchange uncertainty, difficult China comparisons, and the extended timing of onshoring benefits. Highlights significantly outweighed the lowlights.
For the fourth quarter of 2026, local currency sales growth is forecast at approximately 5%, adjusted EPS is forecast to be in the range of $14.84 to $15.04, representing a growth rate of 11% to 13%, and pricing is expected to be in that 2.5 percent range; for full year 2026, local currency sales growth is forecast at approximately 5%, reflecting organic growth of 4%, and adjusted EPS is forecast to be in the range of $47.70 to $47.90, representing a growth rate of 12%. For 2027, local currency sales are expected to increase approximately 5%, adjusted EPS is forecast to be in the range of $52.50 to $53.50, representing a growth rate of 10% to 12%, foreign exchange is estimated to be a 1% headwind to sales growth and neutral to EPS, price is expected to be just over 2% and volume in the 3% ish kind of a range, lab is guided mid to high single digit, core industrial mid-single-digit, product inspection low to mid single digit, food retailing low single digit, The Americas mid to high single digit, Europe low single digit, and China mid single digit; total amortization is expected to be approximately $76 million, purchased intangible amortization approximately $27 million on a pretax basis for approximately $1 per share, interest expense $68 million, other income approximately $22 million, the tax rate before discrete items 18%, free cash flow approximately $950 million, representing 8% growth on a per share basis, and share repurchases $950 million.
- Broad-Based Third-Quarter GrowthThird-quarter sales were $1.1 billion, up 6% in U.S. dollars and local currencies, with organic local-currency sales also up 6%. Growth was broad based across the portfolio and benefited from improving market demand, stronger sales volume, and execution of strategic initiatives.
- Strong Regional Performance in Asia and Emerging MarketsOrganic sales increased 13% in Asia and the rest of the world, including 13% growth in China. Other emerging markets also grew double digits, and management cited strong growth across the portfolio in the region.
- Improved Profitability and Adjusted EPS GrowthGross margin increased 60 basis points to 59.8%, adjusted operating profit rose 8% to $333.5 million, and adjusted operating margin increased 40 basis points to 30.5%. Adjusted EPS was $12.57, up 13% year over year; reported EPS was $12.29 versus $10.57 in the prior year.
- Gross Margin Benefits from Pricing, Tariffs, and VolumeGross-margin expansion was driven by favorable price realization, lower tariff rates compared with the prior year, and volume growth, partially offset by higher material and transportation costs.
- Laboratory Business Growth and RecoveryOrganic laboratory sales increased 6% in the quarter, with broad-based growth across nearly all product areas. Management cited improving biopharma and biotech research trends, strong liquid-handling growth, better quality-lab activity, and strength in pipettes and other research-and-development applications.
- Strength in Industrial and Product InspectionOrganic industrial sales increased 6%, including 5% growth in core industrial and 8% growth in product inspection. Core industrial growth was led by automation and digitalization solutions, while product inspection benefited from strong results across the portfolio and the mid-market strategy.
- Service Revenue GrowthService revenue increased 7% in the quarter.
- Innovation and New Product IntroductionsThe company launched an online bioburden analyzer for real-time monitoring of microbial contamination in applications such as pharmaceutical water systems, introduced the ACT305 weighing transmitter for fast and accurate weight-data transmission and process control, and added AI-enabled image-recognition software for X-ray systems to improve contamination detection while reducing false rejects.
- Digitalization, Automation, and AI PositioningManagement said the company has invested in digital capabilities, sensors, instruments, data infrastructure, and platforms such as LabX that connect instruments across laboratory environments and integrate with customers' AI software. The company sees strong customer interest in self-driving labs, automated experiments, and AI-enabled process optimization, although management described these trends as still in the early stages.
- Strategic Investments Strengthening Competitive PositionRecent investments have accelerated innovation, expanded digital capabilities, enhanced the Spinnaker sales and marketing excellence program, strengthened the product portfolio, and improved global supply-chain resilience and agility.
- Raised Full-Year 2026 OutlookThe company increased its full-year 2026 local-currency sales-growth forecast from approximately 4% to 5% to approximately 5%, reflecting organic growth of 4%. Adjusted EPS is forecast at $47.70 to $47.90, representing 12% growth.
- Fourth-Quarter Earnings GuidanceFourth-quarter 2026 local-currency sales growth is forecast at approximately 5%. Adjusted EPS is expected to be $14.84 to $15.04, representing growth of 11% to 13%. Foreign exchange is not expected to significantly impact results at recent spot rates.
- Positive 2027 Financial OutlookFor 2027, management expects local-currency sales to increase approximately 5% and adjusted EPS to reach $52.50 to $53.50, representing growth of 10% to 12%. Free cash flow is expected to be approximately $950 million, up 8% on a per-share basis, while share repurchases are also expected to be $950 million.
- Expected 2027 Operating Margin ExpansionAt the midpoint of the 2027 adjusted EPS range, management expects operating-margin improvement of approximately 70 basis points, or approximately 90 basis points at the high end of the range. Gross-margin expansion is expected to be flattish or slightly positive.
- China Momentum and Portfolio AlignmentManagement reported strong industrial and laboratory performance in China, with industrial growth in the mid-teens and laboratory growth in the very high single digits in the quarter. China is expected to deliver mid-teens growth in the fourth quarter, and management cited alignment with investment priorities in life sciences, technology, new materials, clean energy, automation, and digitalization.
- Growth Expectations Across 2027 Businesses and RegionsFor 2027, management expects laboratory growth in the mid- to high-single digits, core industrial growth in the mid-single digits, product inspection growth in the low- to mid-single digits, food retail growth in the low single digits, Americas growth in the mid- to high-single digits, Europe growth in the low single digits, and China growth in the mid-single digits.
- Onshoring and Reshoring OpportunityManagement reported increasing onshoring and reshoring activity, customer engagement, leads, and project activity, particularly in the United States. These projects typically have a multiyear cycle, with new facilities potentially taking 2 to 5 years to generate significant momentum. Management expects the activity to contribute in the second half of 2027 and the years ahead, although it has not assumed a meaningful impact in the 2027 results guidance.
- Positive Replacement-Demand TrendsManagement reported good activity for categories that lend themselves to replacement, including analytical instruments and laboratory balances, and expects the current level of activity to continue into 2027. The company has not built an acceleration in replacement demand into its guidance.
- Spinnaker and Market-Share InitiativesManagement expects the Spinnaker program to support incremental market-share gains each year and said the program continues to increase in sophistication. Spinnaker is also being used to identify onshoring-related investments and guide the sales force toward those opportunities.
- Emerging-Market Investment and ScaleThe company has dedicated direct-sales organizations and strategic growth plans across Southeast Asia, India, Korea, Eastern Europe, and Latin America, with incremental investment opportunities under consideration for 2027. Emerging markets outside China account for approximately 17% of sales, while China is expected to represent approximately 17% of sales in 2026.
- Cash Flow Excluding Tax Timing ImpactYear-to-date adjusted free cash flow was $652 million. Excluding taxes, free cash flow per share increased 7% versus the prior year.
MX:MTD Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 11, 2027 | 2026 (Q4) | 277.43- | 248.54 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 225.62233.84 | 207.42 | 12.74% (+26.42) | |
| Jul 30, 2026 | 2026 (Q2) | 201.90213.19 | 187.7 | 13.58% (+25.49) | |
| May 07, 2026 | 2026 (Q1) | 162.07165.75 | 152.36 | 8.79% (+13.39) | |
| Feb 05, 2026 | 2025 (Q4) | 238.15248.54 | 230.86 | 7.66% (+17.67) | |
| Nov 06, 2025 | 2025 (Q3) | 198.27207.42 | 189.94 | 9.21% (+17.49) | |
| Jun 30, 2025 | 2025 (Q2) | 178.53187.70 | 179.52 | 4.56% (+8.19) | |
| May 01, 2025 | 2025 (Q1) | 146.63152.36 | 165.38 | -7.87% (-13.02) | |
| Feb 06, 2025 | 2024 (Q4) | 218.08230.86 | 174.87 | 32.02% (+55.99) | |
| Nov 07, 2024 | 2024 (Q3) | 186.27189.94 | 182.31 | 4.18% (+7.63) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
